Perrigo Stock Hits New 52-Week High (PRGO)

NEW YORK ( TheStreet) -- Perrigo Company (Nasdaq: PRGO) hit a new 52-week high Friday as it is currently trading at $117.25, above its previous 52-week high of $117.16 with 26,452 shares traded as of 9:40 a.m. ET. Average volume has been 673,100 shares over the past 30 days.

Perrigo has a market cap of $10.91 billion and is part of the health care sector and drugs industry. Shares are up 20% year to date as of the close of trading on Thursday.

Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API) worldwide. The company has a P/E ratio of 29.6, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Perrigo as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Perrigo Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

If you liked this article you might like

McDonald's Takes Bite Out of Dow, but Nasdaq and S&P 500 at Records

Perrigo Stock Jumps as Starboard's Smith Says Generic Drugs a Strong Business

Valeant CEO Confident Divestitures Can Successfully Pare Debt, Skeptics Remain

These Stocks Have Changed Direction

Stocks Tank as Trump, North Korea Exchange Barbs